

# Resource Summary Report

Generated by [RRID](#) on Jul 31, 2026

## E2F-1 Antibody

RRID:AB\_2096936

Type: Antibody

### Proper Citation

Cell Signaling Technology Cat# 3742, RRID:AB\_2096936

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2096936](http://antibodyregistry.org/AB_2096936)

**Proper Citation:** Cell Signaling Technology Cat# 3742, RRID:AB\_2096936

**Target Antigen:** E2F1

**Host Organism:** rabbit

**Clonality:** polyclonal

**Comments:** Applications: W, ChIP. Consolidation on 10/2018: AB\_10695245, AB\_2096936.

**Antibody Name:** E2F-1 Antibody

**Description:** This polyclonal targets E2F1

**Target Organism:** rat, mouse, human

**Antibody ID:** AB\_2096936

**Vendor:** Cell Signaling Technology

**Catalog Number:** 3742

**Record Creation Time:** 20250820T060331+0000

**Record Last Update:** 20250820T231124+0000

### Ratings and Alerts

- ENCODE PROJECT External validation for lot: 4 is available under ENCODE ID: ENCAB851KCY - ENCODE

No alerts have been found for E2F-1 Antibody.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 27 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Goerg A, et al. (2025) Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior to mdm2 inhibition. BMC cancer, 25(1), 978.

Jiang X, et al. (2025) KRASG12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC. Cell reports. Medicine, 6(2), 101966.

Shah K, et al. (2025) LncRNA SLNCR phenocopies the E2F1 DNA binding site to promote melanoma progression. Cell reports, 44(5), 115608.

Ren L, et al. (2025) Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses. Cancer cell.

Palmer CL, et al. (2025) CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety. Cancer cell, 43(3), 464.

Zhen Q, et al. (2025) Erucic Acid, Derived by Lactobacillus Crispatus, Induces Ferroptosis in Cervical Cancer Organoids Through the PPAR- $\gamma$  Signaling Pathway. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 12(48), e12599.

Malvi P, et al. (2025) PDE7A inhibition suppresses triple-negative breast cancer by attenuating de novo pyrimidine biosynthesis. Cell reports. Medicine, 6(9), 102356.

Coleman JC, et al. (2024) The RNA binding proteins LARP4A and LARP4B promote sarcoma and carcinoma growth and metastasis. iScience, 27(4), 109288.

Liang J, et al. (2024) Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma. Cell reports, 43(2), 113771.

Pascual-Pasto G, et al. (2024) Targeting GPC2 on Intraocular and CNS Metastatic Retinoblastomas with Local and Systemic Delivery of CAR T Cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(16), 3578.

Sicinska E, et al. (2024) ASPSCR1::TFE3 Drives Alveolar Soft Part Sarcoma by Inducing Targetable Transcriptional Programs. *Cancer research*, 84(14), 2247.

Poliaková Turan M, et al. (2024) E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network. *Cancer research communications*, 4(7), 1863.

Mouery RD, et al. (2024) Proteomic analysis reveals a PLK1-dependent G2/M degradation program and a role for AKAP2 in coordinating the mitotic cytoskeleton. *Cell reports*, 43(8), 114510.

Yu M, et al. (2023) FRMD8 targets both CDK4 activation and RB degradation to suppress colon cancer growth. *Cell reports*, 42(8), 112886.

Zhu GQ, et al. (2022) Targeting HNRNPM Inhibits Cancer Stemness and Enhances Antitumor Immunity in Wnt-activated Hepatocellular Carcinoma. *Cellular and molecular gastroenterology and hepatology*, 13(5), 1413.

Abt ER, et al. (2022) Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in pancreatic cancer cells. *Cell reports*, 38(2), 110236.

Shirakawa J, et al. (2022) E2F1 transcription factor mediates a link between fat and islets to promote  $\beta$  cell proliferation in response to acute insulin resistance. *Cell reports*, 41(1), 111436.

Sanidas I, et al. (2022) Chromatin-bound RB targets promoters, enhancers, and CTCF-bound loci and is redistributed by cell-cycle progression. *Molecular cell*, 82(18), 3333.

Ehteda A, et al. (2021) Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG. *Cell reports*, 35(2), 108994.

Hornsveid M, et al. (2021) A FOXO-dependent replication checkpoint restricts proliferation of damaged cells. *Cell reports*, 34(4), 108675.